Releasable GLP-1 Conjugates via Cleavable Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 conjugates with polyethylene glycol (PEG) face challenges such as reduced potency and altered pharmacokinetic properties due to PEGylation, particularly when linked at the amino terminal or lysine residues, which affects the release and efficacy of the GLP-1 peptide.
Innovation Solution
Development of releasable GLP-1 conjugates where the GLP-1 polypeptide is indirectly bound to an aliphatic polymer like PEG, utilizing a 3′ phosphotriester group that decomposes through intramolecular nucleophilic attack, allowing for controlled release of the GLP-1 peptide with minimal trace of the linker and polymer system, using a trigger moiety that can be enzyme-labile, acid-labile, or pH-labile, providing synthetic freedom and better control over kinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If GLP-1 is conjugated to PEG at amino terminal or lysine residues, then circulation life is extended, but potency is reduced and surface area is blocked
Solution Approach 1:
The conjugate is divided into distinct functional segments: the GLP-1 peptide segment, the PEG polymer segment, and the cleavable linker segment. This segmentation allows each component to perform its specific function - GLP-1 provides biological activity, PEG provides circulation extension, and the linker provides controlled release - while minimizing interference between components.
Solution Approach 2:
A cleavable linker acts as an intermediary between the GLP-1 peptide and the PEG polymer. This linker is designed to remain stable during circulation, maintaining the conjugate structure and preventing direct interaction between PEG and GLP-1 that would block surface area or reduce potency. The linker can be cleaved under specific conditions to release active GLP-1.
2Duration of action of stationary object
If PEG is conjugated to GLP-1, then circulation life is extended and proteolysis is reduced, but surface area is blocked and solubility is hindered
Solution Approach 1:
The harmful effect of PEG blocking surface area is extracted and isolated into a separate linker component that can be removed. By placing the PEG attachment point within a cleavable linker rather than directly on the GLP-1 surface, the PEG's steric hindrance is separated from the peptide's active surface, allowing the peptide to present its binding sites effectively while still benefiting from PEG's circulation-extending properties.
3Ease of manufacture
If conventional conjugation methods are used, then manufacturing is simplified, but release control is poor and polymer residue remains
Solution Approach 1:
The linker is designed with specific chemical parameters that enable controlled cleavage under defined conditions. By adjusting parameters such as the cleavable group type (enzyme-labile, acid-labile, pH-labile) and the timing of cleavage relative to administration, precise control over release timing and extent is achieved while maintaining manufacturing simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables effective and controlled release of biologically active GLP-1 with improved potency and circulation life, overcoming the limitations of existing conjugates by allowing for precise modulation of the release mechanism and minimizing polymer residue on the GLP-1 peptide.
Implementation Method 1
the 3′ phosphotriester group decomposes through intramolecular nucleophilic attack
Implementation Method 2
a trigger moiety that can be enzyme-labile, acid-labile, or pH-labile
Data Source
AI summary
The present application provides compounds of Formula (I):or pharmaceutically acceptable salts thereof, wherein D is a residue of a GLP-polypeptide or an analog thereof, which underdo hydrolysis under physiological conditions to release the GLP-polypeptide or analog thereof and which are useful in the treatment of disorders that could be beneficially treated with the GLP-polypeptide or analog thereof.